NuvaRing® is the trade name for a vaginal contraceptive ring manufactured by Organon. Like other forms of combination hormonal contraception, NuvaRing® contains estrogen and progestin hormones. However, the type of progestin used in the NuvaRing® (etonogestrel), is considered a third-generation progestin and is associated with a greater risk for developing blood clots than the type of progestin that is used in most birth control pills.

Since the NuvaRing® became available in 2002, the U.S. Food and Drug Administration (FDA) has received many reports of adverse events associated with the use of the NuvaRing®. The most dangerous side effect is blood clotting, which can lead to a heart attack, stroke, or even death. In 2005, the FDA required Organon to change the NuvaRing® label to more accurately reflect the risks associated with it.

Schlichter Bogard & Denton is currently representing women who have allegedly been harmed as a result of using the NuvaRing®.

If you or a loved one have suffered one or more of the following conditions while using NuvaRing®, please contact us for a free consultation about your legal rights.

• Blood clot in legs or arms (deep vein thrombosis/DVT)
• Blood clot in the lungs (pulmonary embolism/PE)
• Ishemic Stroke
• Heart Attack

Toll Free: 1-800-USE-LAWS (873-5297)
Tel: (314) 621-6115
Email Kristine Kraft: kkraft@uselaws.com